Page 1 | Search Results | Blood | American Society of Hematology

1-11 of 11

Sort by

Sort Order Select

Journal Articles

Match Date-to-Start Date: Engaging Fellows Pre-Training

Supreet Kaur, Shannon Lovelace, Anand Karnad

Blood (2023) 142 (Supplement 1): 7190.

https://doi.org/10.1182/blood-2023-179440

Published: 2023

Journal Articles

Classical Hematology Referrals at an NCI-Designated Cancer Center: Lessons Learned

Chase West, Matthew James Butler, Supreet Kaur, Anand Karnad

Blood (2022) 140 (Supplement 1): 5025–5026.

https://doi.org/10.1182/blood-2022-158377

Published: 2022

Journal Articles

Combination of Phosphodiesterase 4 (PDE4) Inhibitor Roflumilast and R-CHOP As First-Line Therapy for High-Risk Diffuse Large B Cell Lymphoma Patients

Adolfo Enrique Diaz Duque, Anand Karnad, Matthew James Butler, Elizabeth Bowhay-Carnes, Joel E Michalek, Gabriela Huelgas, Ricardo Aguiar

Blood (2022) 140 (Supplement 1): 6610–6611.

https://doi.org/10.1182/blood-2022-167001

Published: 2022

Journal Articles

Combination of Phosphodiesterase 4 (PDE4) Inhibitor Roflumilast and R-CHOP As First-Line Therapy for High-Risk Diffuse Large B Cell Lymphoma Patients

Adolfo E Diaz, MD, Matthew James Butler, MD, Anand Karnad, MD, Ricardo Aguiar, MD PhD

Blood (2019) 134 (Supplement_1): 1592.

https://doi.org/10.1182/blood-2019-124382

Published: 2019

Journal Articles

Adct-301 (Camidanlumab Tesirine), a Novel Pyrrolobenzodiazepine-Based CD25-Targeting Antibody Drug Conjugate, in a Phase 1 Study of Relapsed/Refractory Non-Hodgkin Lymphoma Shows Activity in T-Cell Lymphoma

Graham P. Collins, MB BS DPhil, Steven M. Horwitz, MD, Andrew Davies, Anand Karnad, MD, Felipe Samaniego, MD, Alexander I Spira, MD, Paul A Fields, MD PhD, Tobias Menne, MD PhD, Joseph Boni, PhD, Hans Cruz, Jay Feingold, MD PhD, Shui He, PhD, Jens Wuerthner, Mehdi Hamadani, MD

Blood (2018) 132 (Supplement 1): 1658.

https://doi.org/10.1182/blood-2018-99-115986

Published: 2018

Journal Articles

Overexpression of BRD4 Is an Adverse Prognostic Factor in Acute Myeloid Leukemia

Hima Bansal, Steven Kornblau, MD, Qiu Yihua, Kevin R Coombes, Subbarayalu Panneerdoss, Anand Karnad, MD, Steven Weitman, MD PhD, Gail Tomlinson, MD PhD, Sanjay Bansal, Swami P. Iyer, MD

Blood (2017) 130 (Supplement 1): 3794.

https://doi.org/10.1182/blood.V130.Suppl_1.3794.3794

Published: 2017

Journal Articles

Interim Results from a Phase 1 Study of ADCT-301 (Camidanlumab Tesirine) Show Promising Activity of a Novel Pyrrolobenzodiazepine-Based Antibody Drug Conjugate in Relapsed/Refractory Hodgkin/Non-Hodgkin Lymphoma

Steven M. Horwitz, MD, Mehdi Hamadani, MD, Michelle A. Fanale, MD, Jay Feingold, MD PhD, Alexander I Spira, MD, Paul A Fields, MD PhD, Tobias Menne, MD PhD, Anand Karnad, MD, Alison J. Moskowitz, MD, Catherine Hildyard, MRCP, BA, Shui He, PhD, Joseph Boni, PhD, Graham Collins, MD PhD

Blood (2017) 130 (Supplement 1): 1510.

https://doi.org/10.1182/blood.V130.Suppl_1.1510.1510

Published: 2017

Journal Articles

Taking " Cellfies ": Blood Morphology in the Era of Smartphones

Christos Fountzilas, MD, Isabelle Le, MD, Marcela Mazo-Canola, MD, Elizabeth Bowhay-Carnes, MD, Anand Karnad, MD

Blood (2016) 128 (22): 5942.

https://doi.org/10.1182/blood.V128.22.5942.5942

Published: 2016

Journal Articles

Chemotherapy Relative Dose Intensity and Therapy Efficacy in Hodgkin and Non-Hodgkin Lymphoma: The Effect of Dose Reductions and Delays on Cure

Elizabeth Bowhay-Carnes, MD, Christos Fountzilas, MD, Michelle Janania Martinez, MD, Brandon Konkel, MD, Brandon Stormes, Anand Karnad, MD

Blood (2015) 126 (23): 5092.

https://doi.org/10.1182/blood.V126.23.5092.5092

Published: 2015

Journal Articles

Indatuximab Ravtansine (BT062) in Combination with Lenalidomide and Low-Dose Dexamethasone in Patients with Relapsed and/or Refractory Multiple Myeloma: Clinical Activity in Patients Already Exposed to Lenalidomide and Bortezomib

Kevin R. Kelly, MD, Asher Chanan-Khan, MD, Leonard T Heffner, MD, George Somlo, MD, David S. Siegel, MD PhD, Todd Zimmerman, MD, Anand Karnad, MD, Nikhil C. Munshi, MD, Sundar Jagannath, MD, Allen L. Greenberg, MD, Sagar Lonial, MD, Vivek Roy, MD, Sikander Ailawadhi, MD, Farima Barmaki-Rad, MD, Shailesh Chavan, MD, Pankaj Patel, PhD, Andrea Wartenberg-Demand, MD, Thomas Haeder, PhD, Kenneth C Anderson, MD

Blood (2014) 124 (21): 4736.

https://doi.org/10.1182/blood.V124.21.4736.4736

Published: 2014

Journal Articles

P53 Based Strategy to Reduce Hematological Toxicity of Chemotherapy: Emerging Support from a Phase II Trial

Chul S. Ha, MD, Joel Michalek, PhD, Richard Elledge, MD, Kevin R. Kelly, MD, PhD, Suthakar Ganapathy, PhD, Hang Su, PhD, Carol Jenkins, RN, BSN, Athanassios Argiris, MD, Ronan Swords, MD, PhD, Tony Y. Eng, MD, Anand Karnad, MD, Richard Crownover, MD, PhD, Gregory P Swanson, MD, Martin Goros, M.S., Brad H Pollock, MPH, PhD, Zhi-Min Yuan, MD, PhD

Blood (2014) 124 (21): 4809.

https://doi.org/10.1182/blood.V124.21.4809.4809

Published: 2014

NARROW

Match Date-to-Start Date: Engaging Fellows Pre-Training

Classical Hematology Referrals at an NCI-Designated Cancer Center: Lessons Learned

Combination of Phosphodiesterase 4 (PDE4) Inhibitor Roflumilast and R-CHOP As First-Line Therapy for High-Risk Diffuse Large B Cell Lymphoma Patients

Combination of Phosphodiesterase 4 (PDE4) Inhibitor Roflumilast and R-CHOP As First-Line Therapy for High-Risk Diffuse Large B Cell Lymphoma Patients

Adct-301 (Camidanlumab Tesirine), a Novel Pyrrolobenzodiazepine-Based CD25-Targeting Antibody Drug Conjugate, in a Phase 1 Study of Relapsed/Refractory Non-Hodgkin Lymphoma Shows Activity in T-Cell Lymphoma

Overexpression of BRD4 Is an Adverse Prognostic Factor in Acute Myeloid Leukemia

Interim Results from a Phase 1 Study of ADCT-301 (Camidanlumab Tesirine) Show Promising Activity of a Novel Pyrrolobenzodiazepine-Based Antibody Drug Conjugate in Relapsed/Refractory Hodgkin/Non-Hodgkin Lymphoma

Taking " Cellfies ": Blood Morphology in the Era of Smartphones

Chemotherapy Relative Dose Intensity and Therapy Efficacy in Hodgkin and Non-Hodgkin Lymphoma: The Effect of Dose Reductions and Delays on Cure

Indatuximab Ravtansine (BT062) in Combination with Lenalidomide and Low-Dose Dexamethasone in Patients with Relapsed and/or Refractory Multiple Myeloma: Clinical Activity in Patients Already Exposed to Lenalidomide and Bortezomib

P53 Based Strategy to Reduce Hematological Toxicity of Chemotherapy: Emerging Support from a Phase II Trial

Email alerts

ASH Publications

American Society of Hematology

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only